Skip to main content

Table 3 Multivariable logistic regression analyses for TNFi-insensitivity and poor response to a TNFi

From: Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study

CategoryTNFi insensitivityPoor response
OR95% CIpOR95% CIp
GenderFemale1 (reference)1 (reference)
Male0.990.57–1.710.970.770.58–1.030.08
Age category 501 (reference)1 (reference)
51–601.270.69–2.340.441.350.97–1.860.07
61–700.680.35–1.320.251.140.82–1.580.43
 710.790.40–1.550.491.040.74–1.470.83
Duration (year)< 0.51 (reference)1 (reference)
0.5–20.870.47–1.590.651.240.87–1.760.24
2–50.750.37–1.530.431.270.86–1.890.23
≥ 50.510.26–1.010.051.160.81–1.660.43
DAS28-CRP< 2.61 (reference)1 (reference)
2.6–4.10.520.10–2.610.423.710.83–16.530.09
> 4.11.460.31–6.790.636.931.57–30.480.01
RF positivity*0.990.60–1.630.971.080.83–1.410.58
Concomitant use of GC1.711.02–2.870.041.291.00–1.670.05
Dose of MTX (mg/week)01 (reference)1 (reference)
1–61.220.45–3.300.700.860.52–1.450.58
7–90.880.37–2.060.761.040.67–1.600.87
10–150.870.38–1.970.730.930.60–1.430.73
> 150.600.24–1.460.260.690.43–1.110.13
Failure in > 2 csDMARDs0.670.42–1.070.090.860.68–1.080.20
BiologicsIFX1 (reference)1 (reference)
ETA1.630.77–3.440.201.190.84–1.690.33
ADA1.030.53–2.000.940.590.43–0.83< 0.01
GLM2.190.42–11.400.351.950.80–4.770.14
CZP2.641.32–5.280.010.640.41–0.980.04
PhaseI + II1 (reference)1 (reference)
III1.300.71–2.380.390.650.49–0.880.01
  1. DAS28 disease activity score for 28 joints, CRP c-reactive protein, MTX methotrexate, GC glucocorticoid, OR odds ratio, CI confidence interval
  2. *RF > 20 IU/mL was defined as positive
  3. p < 0.05